arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Vor Biopharma Inc.

VOR
$18.66 ▼ -1.45 (-7.21%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
18 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Vor Biopharma Inc. shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.1B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 33.7% ↗
FCF / Share $-0.55 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-219.58M
↓ -575.9% —
FCF / Share Free cash flow per share
$-0.55
↓ -17.0% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 178.7% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.21x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 28 quarters